Analysis of the GDSC database revealed that SRS is negatively correlated with IC50s of certain drugs, including Vinblastine, BHG712, XMD8-85, Bortezomib, and Paclitaxel, suggesting that higher SRS expression may be associated with increased sensitivity to these drugs in glioma (Fig 6E). The gene discussed is SMS; the disease is central nervous system cancer.